145 related articles for article (PubMed ID: 12799647)
1. Inhibition of epidermoid carcinoma A431 cell growth and angiogenesis in nude mice by early and late treatment with a novel dextran derivative.
Di Benedetto M; Starzec A; Vassy R; Perret GY; Crépin M; Kraemer M
Br J Cancer; 2003 Jun; 88(12):1987-94. PubMed ID: 12799647
[TBL] [Abstract][Full Text] [Related]
2. Carboxymethyl benzylamide dextran inhibits angiogenesis and growth of VEGF-overexpressing human epidermoid carcinoma xenograft in nude mice.
Hamma-Kourbali Y; Starzec A; Vassy R; Martin A; Kraemer M; Perret G; Crépin M
Br J Cancer; 2003 Jul; 89(1):215-21. PubMed ID: 12838326
[TBL] [Abstract][Full Text] [Related]
3. Aponecrotic, antiangiogenic and antiproliferative effects of a novel dextran derivative on breast cancer growth in vitro and in vivo.
Di Benedetto M; Starzec A; Colombo BM; Briane D; Perret GY; Kraemer M; Crépin M
Br J Pharmacol; 2002 Apr; 135(8):1859-71. PubMed ID: 11959788
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
[TBL] [Abstract][Full Text] [Related]
5. Roles of cell adhesion molecules in tumor angiogenesis induced by cotransplantation of cancer and endothelial cells to nude rats.
Tei K; Kawakami-Kimura N; Taguchi O; Kumamoto K; Higashiyama S; Taniguchi N; Toda K; Kawata R; Hisa Y; Kannagi R
Cancer Res; 2002 Nov; 62(21):6289-96. PubMed ID: 12414659
[TBL] [Abstract][Full Text] [Related]
6. The suppression of fibroblast growth factor 2/fibroblast growth factor 4-dependent tumour angiogenesis and growth by the anti-growth factor activity of dextran derivative (CMDB7).
Bagheri-Yarmand R; Kourbali Y; Mabilat C; Morère JF; Martin A; Lu H; Soria C; Jozefonvicz J; Crépin M
Br J Cancer; 1998 Jul; 78(1):111-8. PubMed ID: 9662260
[TBL] [Abstract][Full Text] [Related]
7. Involvement of CTGF, a hypertrophic chondrocyte-specific gene product, in tumor angiogenesis.
Shimo T; Nakanishi T; Nishida T; Asano M; Sasaki A; Kanyama M; Kuboki T; Matsumura T; Takigawa M
Oncology; 2001; 61(4):315-22. PubMed ID: 11721179
[TBL] [Abstract][Full Text] [Related]
8. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis.
Giavazzi R; Sennino B; Coltrini D; Garofalo A; Dossi R; Ronca R; Tosatti MP; Presta M
Am J Pathol; 2003 Jun; 162(6):1913-26. PubMed ID: 12759248
[TBL] [Abstract][Full Text] [Related]
9. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
[TBL] [Abstract][Full Text] [Related]
10. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth.
Fahmy RG; Dass CR; Sun LQ; Chesterman CN; Khachigian LM
Nat Med; 2003 Aug; 9(8):1026-32. PubMed ID: 12872165
[TBL] [Abstract][Full Text] [Related]
11. A radicicol derivative, KF58333, inhibits expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenografts.
Kurebayashi J; Otsuki T; Kurosumi M; Soga S; Akinaga S; Sonoo H
Jpn J Cancer Res; 2001 Dec; 92(12):1342-51. PubMed ID: 11749701
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor 165 (VEGF(165)) activities are inhibited by carboxymethyl benzylamide dextran that competes for heparin binding to VEGF(165) and VEGF(165).KDR Complexes.
Hamma-Kourbali Y; Vassy R; Starzec A; Le Meuth-Metzinger V; Oudar O; Bagheri-Yarmand R; Perret G; Crépin M
J Biol Chem; 2001 Oct; 276(43):39748-54. PubMed ID: 11514538
[TBL] [Abstract][Full Text] [Related]
13. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.
Viloria-Petit A; Crombet T; Jothy S; Hicklin D; Bohlen P; Schlaeppi JM; Rak J; Kerbel RS
Cancer Res; 2001 Jul; 61(13):5090-101. PubMed ID: 11431346
[TBL] [Abstract][Full Text] [Related]
14. A quantative in vivo method of analyzing human tumor-induced angiogenesis in mice using agarose microencapsulation and hemoglobin enzyme-linked immunosorbent assay.
Okada N; Fushimi M; Nagata Y; Fukunaga T; Tsutsumi Y; Nakagawa S; Mayumi T
Jpn J Cancer Res; 1995 Dec; 86(12):1182-8. PubMed ID: 8636008
[TBL] [Abstract][Full Text] [Related]
15. Distinct heparin binding sites on VEGF165 and its receptors revealed by their interaction with a non sulfated glycoaminoglycan (NaPaC).
Di Benedetto M; Starzec A; Vassy R; Perret GY; Crépin M
Biochim Biophys Acta; 2008 Apr; 1780(4):723-32. PubMed ID: 18325345
[TBL] [Abstract][Full Text] [Related]
16. A novel hypoxia-dependent 2-nitroimidazole KIN-841 inhibits tumour-specific angiogenesis by blocking production of angiogenic factors.
Shimamura M; Nagasawa H; Ashino H; Yamamoto Y; Hazato T; Uto Y; Hori H; Inayama S
Br J Cancer; 2003 Jan; 88(2):307-13. PubMed ID: 12610518
[TBL] [Abstract][Full Text] [Related]
17. Cytostatic and pro-apoptotic effects of a novel phenylacetate-dextran derivative (NaPaC) on breast cancer cells in interactions with endothelial cells.
Malherbe S; Crépin M; Legrand C; Wei MX
Anticancer Drugs; 2004 Nov; 15(10):975-81. PubMed ID: 15514567
[TBL] [Abstract][Full Text] [Related]
18. The alpha(1)beta(1) and alpha(2)beta(1) integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis.
Senger DR; Perruzzi CA; Streit M; Koteliansky VE; de Fougerolles AR; Detmar M
Am J Pathol; 2002 Jan; 160(1):195-204. PubMed ID: 11786413
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity.
Mu J; Abe Y; Tsutsui T; Yamamoto N; Tai XG; Niwa O; Tsujimura T; Sato B; Terano H; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1996 Sep; 87(9):963-71. PubMed ID: 8878460
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.
Kim KJ; Li B; Winer J; Armanini M; Gillett N; Phillips HS; Ferrara N
Nature; 1993 Apr; 362(6423):841-4. PubMed ID: 7683111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
